Tuesday, October 20, 2026 from 8:30 a.m. to 10:00 a.m. MDT at Salt Palace Convention Center - Room 151 D-G
Authors of the recently published expert consensus recommendations will speak on beta-lactam dose individualization in acutely ill patients and the integration of clinical pharmacists into acute stroke care teams. Presenters will review the evidence, key implementation considerations, and practical strategies for optimizing medication-related outcomes, improving treatment timeliness, and overcoming barriers to adoption in clinical practice.
Consensus Recommendation Highlights: Beta-Lactam Dose Individualization8:30 a.m. to 9:15 a.m.
Available for 0.75 hours of CPE credit
Activity Number: 0217-0000-26-209-L01-P
Activity Type: A Knowledge-Based Activity
Clinicians will learn the evidence supporting beta-lactam dose individualization related to effectiveness and safety outcomes for acutely ill patients at risk for variable drug exposures. This session will review international consensus recommendations and provide practical guidance on when and how to implement individualized dosing in clinical practice. Key considerations will include minimum implementation requirements, sampling strategy, assay selection, interpretation of measured concentrations, and common barriers to adoption. Learning Objectives1. Describe the clinical impact of beta-lactam dose individualization on efficacy and safety outcomes in acutely ill patients. 2. Identify the minimum requirements necessary to implement beta-lactam dose individualization in clinical practice. 3. Summarize the technical and methodological considerations necessary to achieve beta-lactam dose individualization, including sampling strategy and assay selection.  | | Speaker: | Nathaniel J. Rhodes, Pharm.D., MSC, BCPS, AQ-ID | | Professor of Pharmacy Practice
Fellowship Director and Clinical and Computational Science Lead
Pharmacometrics Center of Excellence
College of Pharmacy, Downers Grove Campus
Midwestern University
555 31st Street
Downers Grove, Illinois 60515 | | View Biography |
|
|
Consensus Recommendation Highlights: The Acute Stoke Care Team9:15 a.m. to 10:00 a.m.
Available for 0.75 hours of CPE credit
Activity Number: 0217-0000-26-210-L04-P
Activity Type: A Knowledge-Based Activity
This session reviews the consensus recommendations supporting clinical pharmacist integration into acute stroke care teams. Presenters will summarize the evidence demonstrating associations between pharmacist involvement and reduced door-to-needle and anticoagulation-reversal times, describe key pharmacist responsibilities during ischemic and hemorrhagic stroke response, and discuss barriers, evidence limitations, staffing considerations, and practical strategies for implementing or expanding pharmacist participation within interdisciplinary stroke programs. Learning Objectives1. Describe the evidence supporting clinical pharmacist involvement in the management of acute ischemic and anticoagulation-associated hemorrhagic stroke. 2. Explain how clinical pharmacist involvement may reduce door-to-needle time for thrombolytic therapy and time to anticoagulation-reversal agent administration. 3. Describe the clinical pharmacist's role in acute stroke response, including treatment assessment, medication management, and team coordination. 4. Discuss barriers, evidence limitations, and operational considerations associated with integrating clinical pharmacists into acute stroke care teams.  | | Speaker: | Caitlin S. Brown, Pharm.D., FCCP, BCCCP | | Associate Professor of Pharmacy & Emergency Medicine
Mayo Clinic Hospital Rochester
Rochester, MN | | View Biography |
|  | | Speaker: | Brian W. Gilbert, II, Pharm.D., MBA, FCCP, FCCM, FNCS, FASHP, FKCHP | | Medical Science Liaison
Innoviva Specialty Therapeutics | | View Biography |
|
|